Sildenafil Citrate Tablet, Film Coated
Product Images NDC 68071-3631

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Sildenafil Citrate (NDC 68071-3631). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Nucare Pharmaceuticals,inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Pdp (68071 3631 3)

Sildenafil Citrate 50 mg film-coated tablets by NuCare Pharmaceuticals, Inc. This label is for a package of 30 tablets, manufactured by Ajanta Pharma Limited, Gujarat. The label includes dosage form, strength, NDC number 68071-3631-3, warnings, storage instructions, and regulatory information. It also references the manufacturer's label for ingredient details.*

FDA Label Image

Sildenafil_fig1.jpg (Sildenafil Fig1)

Line graph depicting the mean change from baseline in sitting systolic blood pressure over 24 hours after dosing with Sildenafil 100 mg versus placebo in healthy volunteers. The x-axis represents time post dose (hours), and the y-axis shows systolic blood pressure change in mmHg.*

FDA Label Image

Sildenafil_fig3 (Sildenafil Fig 3)

A line graph titled 'Mean Standing Systolic Blood Pressure Change from Baseline' showing time postdose in hours on the x-axis and change in systolic blood pressure (mm Hg) on the y-axis. Two lines compare Doxazosin + Placebo and Doxazosin + Sildenafil 50 mg, illustrating their effects over approximately 8 hours postdose.*

FDA Label Image

Sildenafil_fig_4 (Sildenafil Fig 4)

A line graph depicting mean standing systolic blood pressure change from baseline over an 8-hour period after dosing. Two lines compare effects of Doxazosin combined with Sildenafil 100 mg versus Doxazosin combined with placebo, showing blood pressure changes measured in mmHg on the y-axis against time in hours on the x-axis.*

FDA Label Image

Sidenafil_fig_5 (Sildenafil Fig 5)

A line graph titled 'Mean Sildenafil Plasma Concentrations in Healthy Male Volunteers' showing plasma concentration (ng/ml) on the vertical axis and time post dose (hours) on the horizontal axis. The curve represents plasma levels after a commercial tablet dose, peaking early and declining over 24 hours.*

FDA Label Image

Sildenafil-fig7 (Sildenafil Fig7)

A vertical bar chart showing the percentage of patients reporting improved erectile function for various treatments. The x-axis lists treatment groups: Placebo (n=463), Sildenafil Tablets 25 mg (n=214), Sildenafil Tablets 50 mg (n=391), and Sildenafil Tablets 100 mg (n=380). The y-axis represents the percentage, ranging from 0% to 100%. Each bar displays the corresponding improvement percentages: 24% for placebo, 63% for 25 mg, 74% for 50 mg, and 82% for 100 mg Sildenafil tablets.*

FDA Label Image

Str (Sildenafil Structure)

Chemical structure diagram of Sildenafil, the active ingredient in Sildenafil Citrate 50 mg film-coated tablets by NuCare Pharmaceuticals, Inc. The diagram shows the molecular framework and functional groups of sildenafil.*

FDA Label Image

Figure2 (Sildenafil Fig2)

A line graph comparing the effect on blood pressure (change in DBP mmHg) over time (hours) after administration of doxazosin with placebo versus doxazosin with sildenafil 25 mg. The x-axis represents time postdose in hours, and the y-axis shows the change in diastolic blood pressure. Two lines are shown: one for doxazosin plus placebo and one for doxazosin plus sildenafil 25 mg, illustrating their respective blood pressure changes over an 8-hour period.*

FDA Label Image

Sildenafil_fig6b (Sildenafil Fig6b)

A bar graph depicting the percentage of patients at endpoint across baseline scores ranging from 0 to 5. The graph includes multiple grouped bars for each baseline score category, representing different data subsets with varying heights on the vertical axis that measures the percentage of patients, from 0% to 80%.*

FDA Label Image

Sildenafil_fig6a (Sildenafil Figure6a)

A bar graph displaying the percentage of patients at endpoint across baseline scores ranging from 0 to 5. The x-axis represents baseline scores, while the y-axis shows the percentage of patients. Multiple data series are differentiated by varying bar heights and a legend on the right side.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.